Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:

NCT ID: NCT05691244 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

A Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Start date: April 2023
Phase: Phase 3
Study type: Interventional

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, we now plan to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

NCT ID: NCT05689528 Completed - Clinical trials for Acute Ischemic Stroke

The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke

Start date: July 1, 2017
Phase:
Study type: Observational

Neuroprotection is expected to be an important therapeutic strategy for acute ischemic stroke(AIS), but almost all neuroprotective drugs proved effective in rodent models have failed after entering clinical trials. This study aims to screen the differentially expressed proteins in peripheral blood of patients with acute ischemic stroke and with further study in the animal model of non-human primate cerebral infarction, we may determine the biomarkers that can evaluate the efficacy of neuroprotective drugs.

NCT ID: NCT05686642 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Start date: March 31, 2023
Phase: Phase 2
Study type: Interventional

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

NCT ID: NCT05684172 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Intra-arterial TNK Following Successful EVT in Patients With Large Vessel Occlusion AIS

Start date: January 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Rationale: Recently, one prospective multicenter RCT reported a potential beneficial effect of intra-arterial alteplase following successful endovascular thrombectomy (EVT) in patients with an acute intracranial large vessel occlusion. In 2018, another prospective multicenter RCT supported the superiority of tenecteplase over alteplase in ischemic stroke patients with large vessel occlusion. Objective: To assess the effect of EVT in addition to intra-arterial tenecteplase compared to EVT alone, in patients with large vessel occlusion, on functional and safety outcomes. Study design: This is a parallel group, randomized clinical trial of EVT with IA-TNK versus EVT. The trial has observer blind assessment of the primary outcome and of neuro-imaging at baseline and follow-up. Study population: Patients with acute intracranial large vessel occlusion and an eTICI 2b-3 after EVT. Main study parameters/outcomes: The primary effect parameter will be excellent functional status at day 90 defined as a modified Rankin Score (mRS) of 0-1. The estimate will be adjusted for the known prognostic variables age, pre-stroke mRS, time from onset to randomization, stroke severity (NIHSS) and collaterals and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

NCT ID: NCT05671874 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

Start date: January 16, 2023
Phase: N/A
Study type: Interventional

The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.

NCT ID: NCT05669456 Not yet recruiting - Stroke Clinical Trials

Zeit Alert for Stroke at Home (ZASH) Protocol

ZASH
Start date: January 1, 2023
Phase:
Study type: Observational

This is a single-arm, observational, feasibility study to evaluate if the Halo Alert System can be used in the future to detect stroke events in individuals at risk for stroke wearing the Halo Alert System overnight.

NCT ID: NCT05667103 Not yet recruiting - Stroke Clinical Trials

The Safety and Efficacy of Embotrap Ⅱ in Treating Patients With Acute Ischemic Stroke

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, cohort study aiming to compare the safety and efficacy of EmboTrap II with other stent retrievers without inner channel for acute middle cerebral artery occlusion (MCAO). All enrolled patients will be followed up at 90 days after randomization.

NCT ID: NCT05644938 Enrolling by invitation - Clinical trials for Acute Ischemic Stroke

Optimizing Door-to-reperfusion Times of One-stop Management in Acute Ischemic Stroke

ORETOM
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Time is one of the most important in the decision of treatment of acute ischemic stroke. The optimal One-stop management from admission to recanalization associated with reduction of in-hospital times. The development of flat-detector computed tomography perfusion capable angio-suite allowed One-stop management to be improved treatment time better and better. To compare One-stop management versus our standard workflow in shortening door-to-recanalization time.

NCT ID: NCT05644223 Recruiting - Clinical trials for Acute Ischemic Stroke

Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

EXPAND
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study is a multicenter, prospective, cohort study to observe the clinical efficacy and safety of edaravone dextrol in patients with acute ischemic stroke in a real-world setting.

NCT ID: NCT05632458 Recruiting - Clinical trials for Acute Ischemic Stroke

TWIN2WIN (Double Stent (DS-EVT) Versus Primary Thrombectomy With One Stent (SS-EVT))

Start date: April 21, 2022
Phase: N/A
Study type: Interventional

The use of a double stent retriever (Dual-SR) has been proposed as a safe and effective technique. The invesigators hypothesized that the use of Dual-SR primary could lead to higher first-pass effect rates and better outcomes compared to Single-SR primary. Our goal is to develop a research project to provide additional information on the potential benefits of the simultaneous double stent approach primarily in stroke patients receiving TVS. A randomized study to compare the efficacy of double primary SR versus single primary SR